GB771068A - Process for the preparation of biologically active preparations - Google Patents
Process for the preparation of biologically active preparationsInfo
- Publication number
- GB771068A GB771068A GB24527/54A GB2452754A GB771068A GB 771068 A GB771068 A GB 771068A GB 24527/54 A GB24527/54 A GB 24527/54A GB 2452754 A GB2452754 A GB 2452754A GB 771068 A GB771068 A GB 771068A
- Authority
- GB
- United Kingdom
- Prior art keywords
- protein
- vitamin
- compound
- cobalamin
- volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention comprises a highly effective preparation of a vitamin of the B12 group in dosage unit form, comprising about 2 mg. of a preparation containing about 7 m g. of said vitamin bound to a protein fraction containing intrinsic factor activity and having, in the free state, binding power for vitamins of the B12 group, and the process of preparing biologically active preparations with a component having, in the free state, a binding power for Vitamin B12 or intrinsic factor activity, characterized in that an aqueous solution of a combination of a protein substance with intrinsic factor activity and a vitamin of the B12 group is subjected to fractional precipitation with an alkanol of no more than 2 C atoms, e.g. ethanol, the precipitate formed at alcohol concentrations of about 40 per cent by volume-about 60 per cent by volume being separated, an aqueous solution of this precipitate is then subjected to a fractional salting-out with ammonium sulphate, the fractions precipitated at a saturation of the solution of about 0.7-1.0 being separated after which this precipitate is separated into more or less strongly coloured fractions in aqueous medium by means of electrophonesis and eventually the cobalamin-protein is isolated from the most strongly red-coloured fraction according to well-known methods. Preferably the various process steps are performed at a temperature not exceeding 3 DEG C. and preferably at - 5 DEG C. Zone electrophonesis may be applied using as vehicle cellulose powder, starch, glass powder or other inert vehicles. In an example a physiologically active cobalamin-protein compound is obtained, said compound being of strongly red colour, its Vitamin B12 content corresponding to a ratio of 1 mol. of Vitamin B12 to 1 mol. of said cobalamin-protein compound, said compound containing 1 atom of cobalt per molecule, its Vitamin B12 content being about 13 m g. per mg., said compound being a muco protein compound, having a molecular weight of the order of 100,000, not being dialysable, being soluble in water and physiological sodium chloride solution, being soluble in and not precipitated from its aqueous solutions at an alcohol concentration of 43.7 per cent by volume and precipitating at an alcohol concentration of 56 per cent by volume at a temperature of -5 DEG C. to a pH of about 7.0, its mobility measured in the electrophoresis apparatus of Tiselius (moving boundary method) in phosphate buffer of pH 7.7 and ionic strength 0.1 being at the descending limb - 3.0 x 10-5 cm.2 sec.-1 volt-1, the absorption spectrum of its aqueous solution showing peaks at 550, 518, 413, 363, 324 and 278 mm ., the ratio between the optical densities D413/D550 being about 0.5, that between D363/D550 being about 8.0. Specification 733,875 is referred to.ALSO:The invention comprises a pharmaceutical preparation for treating pernicious anaemia comprising, in dosage unit form, cobalamin-protein (see Group IV(b)), and organs or purified preparations thereof having intrinsic factor activity prepared from animal material such as hog stomach, pylorus or duodenum. Mention is made of a tablet form comprising 0.375 mg of cobalamin-protein with about 1 grm of hog pylorus or stomach or duodenum mucosa, or the corresponding quantity of aqueous extracts, dry powders and like preparations prepared from such mucosa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US771068XA | 1953-08-21 | 1953-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB771068A true GB771068A (en) | 1957-03-27 |
Family
ID=22136095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB24527/54A Expired GB771068A (en) | 1953-08-21 | 1954-08-23 | Process for the preparation of biologically active preparations |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB771068A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1979000880A1 (en) * | 1978-04-04 | 1979-11-01 | R Allen | Quantitative testing for vitamin b12 |
-
1954
- 1954-08-23 GB GB24527/54A patent/GB771068A/en not_active Expired
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1979000880A1 (en) * | 1978-04-04 | 1979-11-01 | R Allen | Quantitative testing for vitamin b12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2099350C1 (en) | Associates of the deprotonized hyaluronic acid, a method of their preparing, pharmaceutical composition containing associates of the deprotonized hyaluronic acid and a method of its preparing | |
Krieger et al. | Acrodermatitis enteropathica without hypozincemia: therapeutic effect of a pancreatic enzyme preparation due to a zinc-binding ligand | |
Wasserman et al. | Vitamin D3 and unidirectional calcium fluxes across the rachitic chick duodenum | |
KR890004687B1 (en) | Sustained releasing dosage forms of biologically active substances | |
DE3280408T2 (en) | CANCER-PREVENTING MEDICINES FOR THE TREATMENT OF T-LEUKAEMIA, COMPOSED FROM THE A-CHAIN OF RIZINUS AND A SPECIFIC MONOCLONAL ANTIBODY. | |
Halliday et al. | Iron absorption in the rat: the search for possible intestinal mucosal carriers | |
DD238529A5 (en) | PROCESS FOR PREPARING A PHARMACEUTICAL PREPARATION WITH A CONTENT OF IBUPROFEN | |
HUT38263A (en) | Process for rendering active substances soluble and production of therapeutic compositions comprising these substances | |
DE2433883A1 (en) | PROTECTED POLYPEPTIDE, IN ESSENTIAL NON-IMMUNOGENIC, ENZYMICALLY ACTIVE SUBSTANCE AND PROCESS FOR EXTENSIVE SUPPRESSION OF THE IMMUNOGENICITY OF A POLYPEPTID | |
DE3876997T2 (en) | CONJUGATES OF SUPEROXIDE DISISMUTASE. | |
EP2994152B1 (en) | Conjugates for protection from nephrotoxic active substances | |
WO2002005844A2 (en) | Protein complex serving as a vehicle for orally administerable medicaments | |
DE69002927T2 (en) | Semi-synthetic derivatives with an immunomodulating effect, suitable for parenteral or oral administration. | |
US3409605A (en) | Concentration and purification of growth factor-placental origin (human) | |
Barteling | A simple method for the preparation of agarose | |
GB771068A (en) | Process for the preparation of biologically active preparations | |
Kopp et al. | Separation of iron-containing ferritin from horse-spleen into three distinct fractions by starch-gel electrophoresis | |
JPS6039647B2 (en) | Method for isolating gamma-L-glutamyl-taurine | |
EP0599142A2 (en) | Method for making immuno-conjugates | |
Krotoski et al. | Peptide-associated and antigenic changes accompanying periodic acid oxidation of human plasma orosomucoid | |
DE2814121C3 (en) | Process for the preparation of a specific immune serum useful in cancer diagnosis K K Saikin Kagaku Kenkyujo, Sendaishi | |
US2892754A (en) | Process of preparing vitamin b12-intrinsic factor | |
DE2333740C2 (en) | Use of a hemagglutination inhibition method to detect cancer | |
McCance et al. | Cholinesterase activity in the secretions of the pancreas of the dog and parotid of the pig | |
NZ182682A (en) | Separating iron compounds from protein in blood substance-containing liquid |